8/102 sources · 2 publishersUpdated Oct 9, 22:26 UTC
TRex Bio completes $116.7 million IPO at $14 per share
TRex Bio Inc. sold roughly 8.3 million shares at $14 each, raising $116.7 million in its U.S. IPO. The offering valued the company at about $384 million and will fund Phase 1b trials of its lead candidate TRB‑061 and future programs. The firm reported a net loss of $34.8 million for 2025, compared with a loss of $3.1 million in the prior year.
Why it matters
The capital infusion will support the company’s clinical development pipeline, extending its cash runway beyond the $90.9 million reported as of June 30 2026. Investors now have a market‑valued entry point at the bottom of the indicated price range.
Key facts
- 1TRex Bio raised $116.7 million through the IPO. finance.yahoo.com
- 2Approximately 8.3 million shares were sold at $14 each. finance.yahoo.com
- 3The IPO price gave the company a market value of about $384 million. finance.yahoo.com
- 4The firm posted a net loss of $34.8 million for 2025, compared with a loss of $3.1 million in the prior year. finance.yahoo.com
- 5Cash, cash equivalents and marketable securities totaled roughly $90.9 million as of June 30 2026. finance.yahoo.com
- 6Lead drug candidate TRB‑061 is in Phase 1b trials, with topline data expected in mid‑2027. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.